Literature DB >> 10328967

Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice.

A Yoshida1, T Fujihara, K Nakata.   

Abstract

Cyclosporin A, an immunosuppressant, has the potential to increase tear fluid secretion through mechanisms which are not yet well understood. To gain insight into this question, we investigated the effect of cyclosporin A containing eyedrops on lacrimation in normal mice. Topical application of 0.1% cyclosporin A eyedrops for 3 days significantly increased lacrimation. This response was completely blocked by pre-exposure to 1% capsaicin. Immunohistochemical analysis revealed that capsaicin treatment depleted substance P from the lacrimal gland. Furthermore, following 1% atropine treatment, which completely blocks pilocarpine-stimulated (500 micrograms kg-1, i.p.) lacrimation, application of 0.1% cyclosporin A eyedrops significantly increased lacrimation. However, this increase was less than the response seen with 0.1% cyclosporin A in the absence of atropine. Interestingly, substance P-induced tear secretion was also partially inhibited in atropine treated mice. These results suggest that cyclosporin A accelerates tear secretion by releasing neurotransmitters from sensory nerve endings which interacts with the parasympathetic nerves. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328967     DOI: 10.1006/exer.1998.0619

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  14 in total

1.  Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model.

Authors:  Hiroshi Toshida; Doan H Nguyen; Roger W Beuerman; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-14       Impact factor: 4.799

2.  The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.

Authors:  Hülya Devecı; Senol Kobak
Journal:  Int Ophthalmol       Date:  2014-01-19       Impact factor: 2.031

Review 3.  The pathophysiology, diagnosis, and treatment of dry eye disease.

Authors:  Elisabeth M Messmer
Journal:  Dtsch Arztebl Int       Date:  2015-01-30       Impact factor: 5.594

Review 4.  Dry eye disease: an immune-mediated ocular surface disorder.

Authors:  William Stevenson; Sunil K Chauhan; Reza Dana
Journal:  Arch Ophthalmol       Date:  2012-01

5.  Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated.

Authors:  Sandeep Samudre; Frank A Lattanzio; Victoria Lossen; Alireza Hosseini; John D Sheppard; Robert L McKown; Gordon W Laurie; Patricia B Williams
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

6.  The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca.

Authors:  Koray Gumus; Dwight H Cavanagh
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 7.  New agents for treating dry eye syndrome.

Authors:  Simon E Skalicky; Con Petsoglou; Avinash Gurbaxani; Clare L Fraser; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

8.  PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.

Authors:  Zahra Sadrai; William Stevenson; Andre Okanobo; Yihe Chen; Thomas H Dohlman; Jing Hua; Francisco Amparo; Sunil K Chauhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-14       Impact factor: 4.799

9.  Treatment of chronic dry eye: focus on cyclosporine.

Authors:  George D Kymionis; Dimitrios I Bouzoukis; Vassilios F Diakonis; Charalambos Siganos
Journal:  Clin Ophthalmol       Date:  2008-12

10.  Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse.

Authors:  Hyesook Lee; Chae Eun Kim; Byul-Nim Ahn; Jaewook Yang
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.